Celltrion Holdings pushing for listing on Nasdaq: sources
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Celltrion Holdings, the parent company of major South Korean pharmaceutical company Celltrion Inc., is pushing for a listing on the Nasdaq stock exchange, industry sources said Monday.
Celltrion Holdings' Chairman Seo Jung-jin announced the company's initial public offering plan during an event hosted by the Federation of Korean Industries a day earlier, according to the sources.
Seo said the company will push for an IPO on the tech-heavy Nasdaq around the end of this year at the earliest, but company officials did not elaborate.
The move comes as part of Celltrion's long-term plan to achieve annual sales of 12 trillion won ($9.08 billion) by 2030 and become a big global industry player.
To reach the target, Celltrion integrated with its sales affiliate Celltrion Healthcare Co. last year and plans to push for an additional merger with its chemical drug-producing affiliate Celltrion Pharm Inc. later this year.
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.